Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT00527657 | Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients | completed | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2018 |
| NCT00568763 | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 11 | Mayo ClinicOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02115243 | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | completed | Phase 1 | 4 | Duke UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT01215500 | Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer | completed | Phase 1 | 63 | University of ChicagoOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01608594 | Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma | completed | Phase 1 | 30 | Diwakar DavarOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT02166255 | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00074308 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2018 | clinicaltrials |
| NCT02696356 | Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma | completed | Phase 1 | 18 | BrightPath BiotherapeuticsINDUSTRY | 1 | Jun 14, 2018 | clinicaltrials |
| NCT02138292 | A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma | completed | Phase 1 | 27 | University of Texas Southwestern Medical CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT01893099 | Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma | completed | Phase 1 | 11 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01943422 | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma(12-107) | completed | Phase 1 | 7 | John KirkwoodOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02668536 | A Sunscreen Based on Bioadhesive Nanoparticles | completed | Phase 1 | 13 | Yale UniversityOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00056134 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 23 | University Hospital ErlangenOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02613325 | fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01079741 | Safety Study of Adjuvant Vaccine to Treat Melanoma Patients | completed | Phase 1 / Phase 2 | 34 | Nina BhardwajOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01711684 | Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) | completed | Phase 1 | 6 | Rockefeller UniversityOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02441465 | Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies | completed | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00715793 | Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma(UPCI-07-008) | completed | Phase 1 / Phase 2 | 39 | Hussein TawbiOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT02574533 | Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma | completed | Phase 1 | 2 | Gradalis, Inc.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00390338 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 | 22 | Pawel KalinskiOTHER | 1 | Sep 26, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01622933 | Multiple Antigen-Engineered DC Vaccine for Melanoma | completed | Phase 1 | 35 | Lisa H. Butterfield, Ph.D.OTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT02935790 | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | completed | Phase 1 | 1 | CelgeneINDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00405587 | Safety Study of PLX4032 in Patients With Solid Tumors | completed | Phase 1 | 109 | PlexxikonINDUSTRY | 2 | Aug 22, 2017 | clinicaltrials |
| NCT00743496 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | completed | Phase 1 | 50 | St. Jude Children's Research HospitalOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01001299 | A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma | completed | Phase 1 | 25 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00062036 | Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 33 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00471471 | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 22 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00125749 | Vaccination of Patients With Stage IV Melanoma With Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00631072 | In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer | completed | Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00457418 | High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) | completed | Phase 1 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00658892 | Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01496807 | Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma | completed | Phase 1 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT01760499 | Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00940004 | Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01530698 | Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients | completed | Phase 1 / Phase 2 | 28 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01065467 | Panobinostat (LBH589) in Patients With Metastatic Melanoma | completed | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01844674 | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Mar 20, 2017 | clinicaltrials |
| NCT00398073 | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT00861406 | Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | completed | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00418496 | Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma | completed | Phase 1 | 17 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00553306 | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01121718 | NIR-Guided Sentinel Lymph Node Mapping in Melanoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 3, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 24, 2019source: clinicaltrials